Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 571 to 585 of 1560 results for do not do recommendations

  1. Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)

    Evidence-based recommendations on chlormethine gel (Ledaga) for treating early-stage mycosis fungoides-type cutaneous T-cell lymphoma in adults.

    Technology appraisal guidance
    Published
    18 August 2021
    View recommendations

    Sections for TA720

  2. Drug misuse prevention (QS165)

    This quality standard covers the prevention or delay of harmful use of drugs by children, young people and adults most likely to start using drugs, or already experimenting or using drugs occasionally. This includes illegal psychoactive substances, solvents, volatile substances, image- and performance-enhancing drugs, prescription-only medicines and over-the-counter medicines. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    29 March 2018
    View quality statements

    Sections for QS165

  3. Does progesterone reduce the risk of preterm birth in women who have risk factors for preterm birth, but do not have a short cervix (cervical length of more than 25 mm)?

    Recommendation ID NG25/5 Question Does progesterone reduce the risk of preterm birth in women who have risk factors for preterm birth,

    Research recommendation
    Published
    25 October 2019

  4. Advance statements and decisions:- What forms of management of violence and aggression do service users prefer and do advance statements and decisions have an important role in management and prevention?

    Recommendation ID NG10/3 Question Advance statements and decisions:- What forms of management of violence and aggression do...

    Research recommendation
    Published
    1 October 2015

  5. Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    15 May 2019
    View recommendations

    Sections for TA580

  6. Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)

    Evidence-based recommendations on ustekinumab (Stelara) for treating moderately to severely active ulcerative colitis in adults.

    Technology appraisal guidance
    Published
    17 June 2020
    View recommendations

    Sections for TA633

  7. Healthy workplaces: improving employee mental and physical health and wellbeing (QS147)

    This quality standard covers the health and wellbeing of all employees, including their mental health. It describes high-quality care in priority areas for improvement. It does not cover managing long-term sickness absence.

    Quality standard
    Published
    3 March 2017
    View quality statements

    Sections for QS147

  8. Supporting healthcare professionals to offer HIV tests:- What interventions are effective and cost effective to increase the likelihood of healthcare professionals offering and recommending an HIV test and of its subsequent uptake?

    Recommendation ID NG60/2 Question Supporting healthcare professionals to offer HIV tests:- What interventions are effective and cost...

    Research recommendation
    Published
    14 February 2017

  9. Recognition of child sexual abuse:- What approaches to practice enable children (both boys and girls) who have been sexually abused to begin to tell practitioners about their experiences earlier, and in a way that does not contaminate the reliability of subsequent court proceedings?

    Recommendation ID NG76/1 Question Recognition of child sexual abuse:- What approaches to practice enable children (both boys and girls)

    Research recommendation
    Published
    18 October 2018

  10. Developmental follow-up of children and young people born preterm (QS169)

    This quality standard covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    18 May 2018
    View quality statements

    Sections for QS169

  11. Liposuction for chronic lipoedema (HTG618)

    Evidence-based recommendations on liposuction for chronic lipoedema in adults. This involves using suction to remove abnormal fat.

    HealthTech guidance
    Published
    29 March 2022
    View recommendations

    Sections for HTG618

  12. Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (HST24)

    Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for treating presymptomatic spinal muscular atrophy in babies aged 12 months and under.

    Highly specialised technologies guidance
    Published
    19 April 2023
    View recommendations

    Sections for HST24

  13. Pirfenidone for treating idiopathic pulmonary fibrosis (TA504)

    Evidence-based recommendations on pirfenidone (Esbriet) for idiopathic pulmonary fibrosis in adults.

    Technology appraisal guidance
    Published
    6 February 2018
    View recommendations

    Sections for TA504

  14. Vandetanib for treating medullary thyroid cancer (TA550)

    Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.

    Technology appraisal guidance
    Published
    12 December 2018
    View recommendations

    Sections for TA550

  15. Suspected neurological conditions: recognition and referral (QS198)

    This quality standard covers assessing and referring children (under 16) and adults (16 and over) who have symptoms or signs associated with neurological conditions. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    8 January 2021
    View quality statements

    Sections for QS198